Janssen&Janssen schreef op 16 augustus 2021 23:09:
Om het maar even luchtig af te sluiten, wederom een onderzoek door medici die niet aan de trial werken dat een C1 inhibitor in grotere relatie staat met Covid-19. En dat het zeer de moeite waard is om hier vervolg onderzoek op te doen, gezien de kansen die het heeft om als strategisch middel te worden ingezet bij Covid patienten
Artikel is van 7 july en gepubliceerd in de Oxford Open Immunology
www.google.com/url?sa=t&source=we...kleine stukje uit het onderzoek:
These findings indicate that plasma protease
inhibitors and inflammation interact both in early and established COVID-19. Accordingly, raised plasma ITIH4 could be developed as a biomarker of COVID-19 severity. Furthermore, the rebalancing of protease inhibitor levels, such as replenishing C1-INH or a2M, could be considered a therapeutic strategy for COVID-19.
This is of particular relevance given the description of clinical improvement in four of five patients treated with hu-man recombinant C1-INH for severe COVID-19 [22]. However, further research is needed to establish whether associations between protease inhibitor changes and COVID-19 are causative and to delineate the mechanisms that explain these associations.
Our data are consistent with data from mass spectrometry-based proteomic analyses of plasma and sera samples from COVID-19 patients. C1-INH was the protein with the most significantly reduced levels in samples from 31 COVID-19 patients compared with 262 controls [23]. From the same study, levels of ITIH4 were increased at first sampling in COVID-19 patients and inpatients who died from COVID-19 [24]. These results replicate associations between COVID-19 severity and C1-INH and ITIH4 identified from an isotope-labelled, targeted proteomic strategy applied to sera from 46 COVID-19 patients and 53 controls